Oral Antiplatelet Therapy in
the Setting of ACS

Focus on Timing, Safety, Bleeding Risk,
and Guidelines for Thienopyridines in the
Setting of CABG Surgery

Webcast CME Disclosure

Please read this notice and click the acknowledgement
at the bottom of the page to continue.

Release Date:

February 1, 2009

Expiration Date:

February 1, 2011

Intended Audience:

This program is designed for all practitioners with the following specialties or subspecialties: emergency physicians, cardiologists, hospitalists and hospital pharmacists.

Registration:

Enrollment for this HealthWRAP is complimentary, and clinicians are invited to participate in this CME-certified HealthWRAPs and/or share this invitation with other colleagues, departmental staff members, and healthcare professionals.

Grantor Support:

The following program has been supported by an independent medical educational grant from the Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership

Accreditation Statement for Jointly-Sponsored Programs:

This activity has been planned and implemented in accordance with the Essentials Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of the University of Massachusetts Medical School and CMEducation Resources, LLC. The University of Massachusetts Medical School is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement:

The University of Massachusetts Medical School designates this educational activity for a maximum of 2 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Disclosure

It is the policy of the University of Massachusetts Medical School to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the University of Massachusetts Medical School are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships with those supporting the activity or others whose products or services are discussed. Faculty disclosure will be provided in the activity materials.

Policy on Faculty & Provider Disclosure:

It is the policy of the University of Massachusetts Medical School to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the University of Massachusetts Medical School are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships with those supporting the activity or others whose products or services are discussed. Faculty disclosure will be provided in the activity materials.

Program Faculty:

Sunil V. Rao, MD, FACC
Host, Duke University Medical Center Cardiac Catheterization Conference
Duke University Medical Center
Director, Cardiac Catheterization Laboratories
Durham VA Medical Center
Durham, North Carolina

Faculty Disclosures:

Dr. Sunil V. Rao, MD, discloses that he has served as a consultant and on Speakers' Bureau for sanofi-aventis, Bristol Myers Squibb, and The Medicines Company; and has received research grants from Momenta Pharmaceuticals, Portola Pharmaceuticals, and Cordis Corporation.

Educational Objectives:

Physicians, pharmacists, and other healthcare providers will:

• Understand the effects that upstream clopidogrel use may have on bleeding, reoperation, transfusion, and other clinical end points in ACS patients undergoing CABG surgery
• Understand what factor and/or combination of predictive factors may influence reoperation, bleeding, and transfusion in ACS patients undergoing CABG surgery
• Learn strategies for reducing the risk of peroperative transfusions, bleeding, and/or reoperation in patients undergoing CABG surgery
• Learn how to evaluate and interpret landmark trials and observational database-generated investigations focused on illuminating the relationship between oral antiplatelet therapy and clinical end points in patients with CABG surgery
• Learn how to optimize oral antiplatelet therapy in patiens with ACS
• Learn about the foundation role of antiplatelet agents when managing acutely ill patients presenting to the ED or CCU with NSTE-ACS or STEMI
• Learn how to interpret and analyze landmark trials to facilitate optimal drug selection to address acute ischemic heart disease, with a focus on the approach to timing, selection, and appropriate use of oral antiplatelet agents in the setting of UA, NSTEMI, and STEMI
• Learn how to initially risk stratify patients presenting with NSTE-ACS, perform dynamic, ongoing risk evaluation, and on the basis of such patient stratification, determine optimal, guidelines-compliant approaches to antithrombotic therapy
• Learn indications and evidence for using oral antiplatelet agents in combination with LMWHs, UFH, IV GP IIb/IIIa receptor antagonists and other antithrombotic therapies in the ED setting
• Learn the implications of the CRUSADE and REACH registries for assessing and illuminating clinical practice gaps in ED-based management of patients with NSTE-ACS and STEMI
• Learn how to analyze, interpret, and apply AHA/ACC guidelines for management of NSTE-ACS and STEMI, with a focus on timing of administration and special considerations depending on risk stratification, invasive vs. non-invasive strategies, and planned CABG
• Learn the actions, pharmacology, dose, and side effects of antiplatelet agents employed in the acute management of ischemic heart disease
• Learn strategies for optimizing clinical outcomes in patients with low, moderate, and high risk features of NSTE-ACS
• Strategies for collaboration between emergency medicine and cardiologists when managing patients presenting to the hospital with NSTE-ACS or STEMI
• Learn how to apply evidence-based and guideline-consistent (ACC. AHA, ACEP, SCAI, ACCP), antiplatelet-based management strategies to acutely ill patients with NSTE-ACS or STEMI
• Learn prescribing strategies that reduce side effects and increase the likelihood of optimal clinical outcomes in patients with acute atheroembolic heart disease
• Learn to characterize and distinguish among safety profiles of and efficacy characteristics of antiplatelet agents used to manage patients across the comprehensive, ischemic cardiovascular morbidity continuum
• Learn the important determinants in choosing reperfusion therapies for STEMI (fibrinolysis vs. primary PCI) and how to maximize the efficacy of either approach with the use of optimal antithrombotic and antiplatelet therapy.
  

Disclaimer:

Copyright © 2009 by CMEducation Resources, LLC and Pharmatecture, LLC All rights reserved. Reproduction, distribution, or translation without express written permission is strictly prohibited.

Content on this HealthWRAP reflects the opinions, output, and analyses of experts, investigators, educators, and clinicians whose activities for, while independent, are commercially supported by the sponsor noted at the start of each activity.
Content on this HealthWRAP is not meant to be, nor substitute for national guidelines or recommendations generated by professional, academic societies, colleges, or associations.

Content on this HealthWRAP is intended for educational value only. Its contents, analyses, and any recommendation made herein are intended to make scientific information and opinion available to health professionals, to stimulate thought, and further investigation. This HealthWRAP is not designed nor is any aspect of the contents here intended to provide advice regarding medical diagnosis or treatment for any individual case. Any decisions regarding diagnosis and/or management of any individual patient or group of patients should be made on individual basis after having consulted appropriate sources, whether they be appropriate consultants and/or guidelines and recommendations issued by national organizations, professional societies, governmental health organizations, or similar bodies. This HealthWRAP is not intended for use by the layman.

Opinions expressed herein are not necessarily those of CMEducation Resources, LLC, Pharmatecture, LLC, program supporters or accreditors, but reflect the opinions and analyses of the experts who have authored the material. Mention of products or services does not constitute endorsement. Clinical, legal, financial, and other comments are offered for general guidance only; and professional counsel should be sought for all specific situations.

Copyright © 2009 All rights reserved